靶向坏死性凋亡作为慢性心肌梗死的治疗潜力。
Targeting necroptosis as therapeutic potential in chronic myocardial infarction.
机构信息
Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
出版信息
J Biomed Sci. 2021 Apr 9;28(1):25. doi: 10.1186/s12929-021-00722-w.
Cardiovascular diseases (CVDs) are considered the predominant cause of morbidity and mortality globally. Of these, myocardial infarction (MI) is the most common cause of CVD mortality. MI is a life-threatening condition which occurs when coronary perfusion is interrupted leading to cardiomyocyte death. Subsequent to MI, consequences include adverse cardiac remodeling and cardiac dysfunction mainly contribute to the development of heart failure (HF). It has been shown that loss of functional cardiomyocytes in MI-induced HF are associated with several cell death pathways, in particular necroptosis. Although the entire mechanism underlying necroptosis in MI progression is still not widely recognized, some recent studies have reported beneficial effects of necroptosis inhibitors on cell viability and cardiac function in chronic MI models. Therefore, extensive investigation into the necroptosis signaling pathway is indicated for further study. This article comprehensively reviews the context of the underlying mechanisms of necroptosis in chronic MI-induced HF in in vitro, in vivo and clinical studies. These findings could inform ways of developing novel therapeutic strategies to improve the clinical outcomes in MI patients from this point forward.
心血管疾病(CVDs)被认为是全球发病率和死亡率的主要原因。在这些疾病中,心肌梗死(MI)是 CVD 死亡率的最常见原因。MI 是一种危及生命的病症,当冠状动脉灌注中断导致心肌细胞死亡时发生。MI 后,后果包括不良的心脏重构和心功能障碍,主要导致心力衰竭(HF)的发展。已经表明,MI 诱导的 HF 中功能性心肌细胞的丧失与几种细胞死亡途径有关,特别是坏死性凋亡。尽管 MI 进展中坏死性凋亡的整个机制尚未得到广泛认可,但一些最近的研究报告了坏死性凋亡抑制剂对慢性 MI 模型中细胞活力和心功能的有益影响。因此,需要对坏死性凋亡信号通路进行广泛的研究。本文全面综述了在体外、体内和临床研究中慢性 MI 诱导的 HF 中坏死性凋亡的潜在机制。这些发现可以为今后从这个角度开发改善 MI 患者临床结局的新治疗策略提供信息。